Research programme: mRNA based cancer vaccines - Moderna Therapeutics/MerckAlternative Names: mRNA based personalised cancer vaccines - Moderna Therapeutics/Merck
Latest Information Update: 18 Oct 2016
At a glance
- Originator Moderna Therapeutics
- Developer Merck AG; Moderna Therapeutics
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer